Literature DB >> 12877253

Estradiol level on day 9 as a predictor of risk for ovarian hyperresponse during controlled ovarian hyperstimulation.

Hsin-Yi Ho1, Robert Kuo-Kuang Lee, Ming-Huei Lin, Yuh-Ming Hwu.   

Abstract

PURPOSE: To investigate the estradiol (E2) level in the mid-follicular phase during controlled ovarian hyperstimulation (COH) and evaluate it as a predictor of a high risk for ovarian hyperresponse.
METHODS: From January 1996 to October 2001, the records of a total of 146 patients undergoing 164 COH cycles were retrospectively reviewed. All patients received the long protocol of GnRH agonists from the previous mid-luteal phase and then hMG or FSH from day 3 of the menstrual cycle. The E2 level was evaluated on day 9. Ovarian hyperresponse was defined as 1) an E2 level on the day of hCG injection was > 4000 pg/mL, or 2) the necessity for coasting during COH to decrease the risk of ovarian hyperstimulation syndrome (OHSS).
RESULTS: Of the 52 cycles in which day 9 E2 level was > 800 pg/mL, 29 (55.8%) fulfilled the criteria for ovarian hyperresponse. None of patients whose day 9 E2 level was < 300 pg/mL met the criteria for hyperresponse. The pregnancy rate in the groups with day 9 E2 level < 300 pg/mL was 42.9%; for an E2 level = 300-800 pg/mL, 49.2%; and for an E2 level > 800 pg/mL, 32.7%. The corresponding implantation rates were 18.8,28.0, and 17.0%. The E2 level on day 9 did not correlate with clinical pregnancy rates or implantation rates.
CONCLUSIONS: A high E2 level in the mid-follicular phase was predictive of patients with a high ovarian response. An E2 level on day 9 of menstrual cycle of > 800 pg/mL suggests an increased risk for ovarian hyperresponse, and appropriate management should be instituted to decrease the risk of OHSS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12877253      PMCID: PMC3455325          DOI: 10.1023/a:1024155411444

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  16 in total

Review 1.  The prevention of ovarian hyperstimulation syndrome.

Authors:  R S Mathur; L A Joels; A V Akande; J M Jenkins
Journal:  Br J Obstet Gynaecol       Date:  1996-08

2.  Prediction of ovarian hyperstimulation syndrome by ultrasound volumetric assessment [corrected] of baseline ovarian volume prior to stimulation.

Authors:  B Danninger; M Brunner; A Obruca; W Feichtinger
Journal:  Hum Reprod       Date:  1996-08       Impact factor: 6.918

Review 3.  Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures.

Authors:  B Rizk; J Smitz
Journal:  Hum Reprod       Date:  1992-03       Impact factor: 6.918

Review 4.  Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment.

Authors:  D Navot; P A Bergh; N Laufer
Journal:  Fertil Steril       Date:  1992-08       Impact factor: 7.329

5.  Low intraovarian vascular resistance: a marker for severe ovarian hyperstimulation syndrome.

Authors:  J M Moohan; K Curcio; M Leoni; D Healy; V Hurley
Journal:  Fertil Steril       Date:  1997-04       Impact factor: 7.329

6.  Withholding gonadotropins ("coasting") to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles.

Authors:  M R Fluker; W M Hooper; A A Yuzpe
Journal:  Fertil Steril       Date:  1999-02       Impact factor: 7.329

7.  Risk factors and prognostic variables in the ovarian hyperstimulation syndrome.

Authors:  D Navot; A Relou; A Birkenfeld; R Rabinowitz; A Brzezinski; E J Margalioth
Journal:  Am J Obstet Gynecol       Date:  1988-07       Impact factor: 8.661

8.  The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features.

Authors:  A Delvigne; A Demoulin; J Smitz; J Donnez; P Koninckx; M Dhont; Y Englert; L Delbeke; L Darcis; S Gordts
Journal:  Hum Reprod       Date:  1993-09       Impact factor: 6.918

9.  The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction.

Authors:  A Delvigne; M Dubois; B Battheu; S Bassil; C Meuleman; P De Sutter; C Rodesch; P Janssens; P Remacle; S Gordts
Journal:  Hum Reprod       Date:  1993-09       Impact factor: 6.918

10.  Exogenous follicle stimulating hormone ovarian reserve test (EFORT): a simple and reliable screening test for detecting 'poor responders' in in-vitro fertilization.

Authors:  R Fanchin; D de Ziegler; F Olivennes; J Taieb; A Dzik; R Frydman
Journal:  Hum Reprod       Date:  1994-09       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.